Impact of COVID-19 on Business Performance
First written in FY2020. 7 of 12 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024DroppedAnnual report
「The COVID-19 pandemic has accelerated the rapid adoption of digital tools across various areas」
In the filing's list of business and other risks, the previously disclosed risk of COVID-19's current impact on results is no longer presented as a standalone item. - FY2023MitigatedAnnual report
「The impact of COVID-19 during the fiscal year under review remained limited, as in the previous fiscal year.」
The disclosure states that the impact of COVID-19 on results was limited and assumes that economic activity will recover to pre-pandemic levels following factors such as the reclassification of COVID-19 to Category 5 under Japan's Infectious Diseases Control Law. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter, negative factors such as restrictions on face-to-face sales due to the COVID-19 pandemic continued, but the business continued to expand.」
The disclosure states that negative factors from COVID-19, including restrictions on face-to-face sales, continued, while the business continued to expand despite them. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter, negative factors such as restrictions on face-to-face sales due to the COVID-19 pandemic continued, but the business continued to expand.」
The disclosure states that the business continued to expand despite the persistence of negative factors such as restrictions on face-to-face sales. It states that there were no new business or other risks or material changes. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter, negative factors such as restrictions on face-to-face sales due to the COVID-19 pandemic continued from the previous fiscal year, but the business continued to expand.」
The disclosure reiterates that negative factors from COVID-19, including restrictions on face-to-face sales, continued, while stating that the business continued to expand despite them. - FY2022RestatedAnnual report
「The impact of COVID-19 during the fiscal year under review remained limited, as in the previous fiscal year.」
The disclosure describes potential impacts from changes in sales practices, patients postponing visits, fewer image-diagnostic requests and lower frequency of pharmacy use, while stating that the impact on full-year results was limited. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter, the impact of fewer image-diagnostic requests per medical institution due to patients refraining from visits amid the continuing COVID-19 pandemic persisted, but a gradual recovery was seen year on year.」
The disclosure states that the impact of fewer image-diagnostic requests due to patients refraining from visits continued, while reporting a gradual year-on-year recovery. It states that there were no material changes in business or other risks. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter, negative factors such as restrictions on face-to-face sales due to the COVID-19 pandemic continued from the previous fiscal year, but the business continued to expand.」
The disclosure reiterates that negative factors from COVID-19, including restrictions on face-to-face sales, continued. It states that there were no new risks or material changes. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter, negative factors such as restrictions on face-to-face sales due to the COVID-19 pandemic continued from the previous fiscal year, but the business continued to expand.」
The disclosure reiterates that negative factors from COVID-19, including restrictions on face-to-face sales, continued, while stating that the business continued to expand despite them. - FY2021-Q3MaterialisedAnnual report
「During the cumulative third quarter, negative factors, including restrictions on face-to-face sales, patients postponing visits and reduced investment by medical institutions due to the COVID-19 pandemic, were evident, but the business continued to expand.」
The disclosure states that restrictions on face-to-face sales, patients postponing visits and reduced investment by medical institutions due to the pandemic continued to affect the business environment. In telemedicine, requests for image diagnostics declined, but revenue had recovered to roughly the year-earlier level as of the end of the third quarter; dispensing-pharmacy support recorded lower revenue and profit due to reduced investment and other factors. - FY2021-Q1MaterialisedAnnual report
「As a result of the COVID-19 pandemic, business activity slowed because visits to health insurance societies, medical institutions and other organizations were curtailed, while demand for ad hoc sales in the data utilization business was temporarily suppressed.」
The infectious disease risk actually affected business activity and demand for ad hoc sales. Revenue from telemedicine declined 7.8% year on year, while revenue from dispensing-pharmacy support declined 8.8%; the disclosure also notes that fewer patients visited medical institutions for consultations and health checkups and that pharmacy foot traffic decreased. - FY2020First statedAnnual report
「The COVID-19 pandemic has had a significant impact on humanity. In the short term, the Group expects slower business activity and patients postponing visits to affect its results.」
The disclosure identified potential impacts on business activity, patient visits, health checkups and pharmacy use as key risks for the first time. It stated that the impact on full-year results was limited.